|
|
|
|
|
|
|
M T W Thu F |
|
25 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I'm back from BIO after an action-packed few days. The sun was shining, the tacos were tasty and the conversations were captivating. In my corner of the biopharma universe — covering the industry's relationship with Washington — China was the talk of the town. There was also a sense of stability and momentum under new FDA leadership, underscored by three acting leaders saying on one panel that they're putting last year behind them.
Anything else that stood out to you if you were there? Drop me a line, as the conference's trends help guide our coverage the rest of the summer and beyond. |
|
|
|
Max Bayer |
Senior Reporter, Endpoints News
|
|
|
|
 |
|
Rod Wong, RTW Investments' chief investment officer |
|
|
|
by Lei Lei Wu
|
Last week, I sat down with Rod Wong, RTW Investments' chief investment officer, at his firm’s office overlooking NYC's Little Island, as New York Knicks'... | |
|
|
|
|
|
|
by Shelby Livingston
|
An FDA committee will meet next month to discuss lifting a ban on a number of peptides marketed for wellness. Compounding pharmacies have been gearing... | |
|
|
|
|
|
|
|
|
by Lei Lei Wu
|
One month after Daiichi Sankyo and AstraZeneca’s drug Datroway received a key breast cancer approval from the FDA, the agency has granted Gilead two approvals... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
Ionis landed an FDA approval on Wednesday that will greatly expand its commercial opportunity for Tryngolza. The antisense drug may now be used to... | |
|
|
|
 |
|
|
|
by Kyle LaHucik
|
Luke Miels made plans for a big cancer deal to grow GSK's small oncology portfolio before he began as CEO at the start of this... | |
|
|
|
|
|
